SASO Tightens RO System Requirements for Medical Use in Saudi Arabia

Saudi Arabia’s Standards, Metrology and Quality Organization (SASO) issued the revised SASO IEC 60601-2-62:2026 standard on 28 May 2026, introducing mandatory new performance and safety requirements for medical-grade reverse osmosis (RO) water systems destined for export to the Kingdom. The update directly impacts manufacturers, exporters, and healthcare infrastructure suppliers, reflecting heightened regulatory focus on water purity for hemodialysis applications.

Key Regulatory Changes Effective Immediately

The SASO IEC 60601-2-62:2026 revision mandates two new core verification tests for all medical RO systems prior to market access:

• Stable water production rate under ≥95% salt rejection over a continuous 72-hour operational cycle;
• Total organic carbon (TOC) concentration in final product water ≤100 ppb at point of use.

Legacy certifications issued under previous versions of the standard are no longer valid as of 28 May 2026. Certified manufacturers must complete re-evaluation and obtain updated certification by 30 November 2026.

Impact Across the Medical Water Equipment Value Chain

Exporters and Distributors

These firms face immediate compliance risk: shipments without valid SASO IEC 60601-2-62:2026 certification will be rejected at Saudi ports. Pre-shipment testing documentation—including full 72-hour stability logs and accredited TOC reports—must now be included in customs and tender submissions.

Raw Material and Component Suppliers

Suppliers of critical subsystems—such as high-rejection membranes, low-leaching tubing, and TOC-resistant storage tanks—must verify material compatibility with the new stability and contamination thresholds. Certifications for components may now need traceability to TOC control protocols.

Manufacturers and System Integrators

Production lines require recalibration for sustained output consistency; automated monitoring systems must log real-time flow, pressure, conductivity, and TOC data for validation. Design validation now includes extended durability testing beyond nominal duty cycles.

Aftermarket and Compliance Support Providers

Service providers offering SASO certification support, third-party testing coordination, or technical documentation review must update their checklists and reporting templates to cover both new test parameters—and ensure alignment with SASO-accredited laboratories in GCC or internationally recognized bodies (e.g., ILAC-MRA signatories).

Priority Actions for Affected Enterprises

Immediate Certification Gap Assessment

Review existing SASO certificates against the 2026 revision’s scope and test clauses. Identify which models require full retesting versus partial updates—especially those previously certified without TOC or long-duration stability validation.

Verification of Testing Infrastructure and Lab Accreditation

Confirm that internal or contracted labs possess SASO-recognized accreditation for TOC analysis (per ISO 8573-7 or equivalent) and can perform 72-hour uninterrupted operational validation under ≥95% desalination conditions.

Revision of Technical Documentation and Tender Submissions

Update user manuals, installation guides, and technical bids to explicitly declare compliance with SASO IEC 60601-2-62:2026—including test methodology summaries, pass/fail criteria, and calibration traceability for TOC sensors and flow meters.

Supplier Qualification Alignment

Require Tier-1 component vendors (e.g., membrane suppliers, pump OEMs, sensor manufacturers) to provide declarations of conformity addressing TOC leaching potential and long-term output stability under specified operating conditions.

Industry Observation: Beyond Compliance Toward Clinical Risk Mitigation

Analysis shows this revision reflects a strategic shift—from energy efficiency and basic safety toward clinical outcome assurance. By anchoring requirements to hemodialysis water quality standards (e.g., AAMI/ISO 13959), SASO is effectively integrating device regulation with patient safety governance. Observably, the 100 ppb TOC limit aligns closely with global best practices for reducing biofilm formation and endotoxin generation in dialysate circuits. What deserves closer attention is the implied expectation for manufacturers to demonstrate system-level contamination control—not just component-level specifications. This elevates design validation from functional testing to clinical process reliability assessment.

Strategic Implications for Global Suppliers

This update signals a broader trend: Gulf Cooperation Council (GCC) regulators are increasingly harmonizing medical device standards with ISO and IEC frameworks—but adding localized operational validation layers. For Chinese and other non-GCC RO system exporters, the revised SASO requirement represents more than a technical hurdle—it marks a transition toward clinical-grade accountability in water treatment equipment. Success hinges not only on passing tests but on embedding traceable, auditable quality controls across R&D, sourcing, manufacturing, and post-market surveillance.

Source Transparency and Ongoing Monitoring

This article is generated exclusively from the user-provided title, event date (28 May 2026), and summary text. Specific official source links were not provided in the input and should be verified continuously. Stakeholders are advised to monitor SASO’s official portal for implementation guidance, laboratory recognition updates, transitional arrangements, and any clarifications regarding test protocol interpretation—particularly concerning TOC sampling methodology and acceptance criteria for intermittent system operation scenarios.